Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|October 22, 2026

The BioPharm Brief: Kidney Approval, Retinal Cell Therapy, and a Breast Cancer Trial Shift

The FDA grants accelerated approval to Ultomiris for IgA nephropathy, Alcon acquires Neurotech and its MacTel cell therapy for $550 million, and BioNTech and Bristol Myers Squibb add Trodelvy to a phase 3 trial in triple-negative breast cancer.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. We’re looking at a new FDA approval for a progressive kidney disease, a major acquisition in retinal cell therapy, and a shift in strategy for a late-stage breast cancer trial.

First, Alexion’s Ultomiris has received FDA accelerated approval to reduce protein in the urine in adults with I-g-A nephropathy who are at risk of disease progression. It is the first drug of its kind, a C5 complement inhibitor, approved for this use. In the phase 3 I CAN trial, Ultomiris reduced urine protein levels by 46.6% at week 34, compared with 5.6% for placebo. It is given by infusion every eight weeks after a loading dose. Because the approval is accelerated, it has not yet been shown that Ultomiris slows the decline in kidney function, and the ongoing trial is designed to confirm that benefit.

Next, Alcon has acquired Neurotech Pharmaceuticals for $550 million. The deal brings Alcon Encelto, the only FDA-approved treatment for macular telangiectasia type 2, or MacTel, a disease that gradually destroys central vision. The therapy is a small capsule of engineered cells, implanted in the eye, that continuously releases a protein designed to protect light-sensing cells in the retina. In two phase 3 trials with 228 participants, the treatment slowed the loss of those cells by 54.8% and 30.6% compared with a sham procedure. About 25,000 people in the United States have been diagnosed with MacTel.

And BioNTech and Bristol Myers Squibb plan to pair their bispecific antibody pumitamig with Gilead’s Trodelvy in a phase 3 trial in first-line triple-negative breast cancer. Pending regulatory approval, the antibody-drug conjugate will replace chemotherapy in the trial’s combination arm for patients whose tumors have low or no PD-L1. The change reflects Trodelvy’s approval as a first-line treatment in June, after it extended median progression-free survival to 9.7 months, compared with 6.9 months for chemotherapy. The trial plans to enroll 558 patients, and the safety and efficacy of the new combination have not yet been established.

That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways

  • Insulin supply resilience: Public funding is now tied directly to production and stockpiling obligations for Sanofi’s new Frankfurt insulin plant.
  • Bispecific vs. standard of care: EA2251 will test ivonescimab against immunotherapy-based regimens, not chemotherapy alone, in first-line biliary tract cancer.
  • Longer dosing intervals: TMB-365’s host-directed mechanism and receptor occupancy data support its development as a backbone for long-acting HIV regimens.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more